


8TH ANNUAL BRAIN METASTASES RESEARCH AND EMERGING THERAPY CONFERENCE
SEPTEMBER, 21-22 2018 • MARSEILLE, FRANCE

Activities of EORTC BTG CNS Metastases Committee

Emilie Le Rhun
Lille, France




[ACTIVITIES](#)
[RESEARCH FIELDS](#)
[NETWORK & PARTNERS](#)
[RESEARCH TOOLS](#)
[ABOUT US](#)
[TUMOURS](#)
[BRAIN](#)
[BREAST](#)
[CHILDREN LEUKEMIA](#)
[CUTANEOUS LYMPHOMA](#)
[ENDOCRINE](#)
[GASTRO INTESTINAL](#)
[GENITO-URINARY](#)
[GYNECOLOGICAL](#)
[HEAD & NECK](#)
[LEUKEMIA](#)
[LUNG](#)
[LYMPHOMA](#)
[MELANOMA](#)
[SOFT TISSUE & BONE](#)
[TUMOURS](#)

BRAIN

[Description](#)
[News](#)
[Clinical Trials](#)
[Achievements](#)
[Projects](#)
[People](#)
[Publications](#)

Description

The EORTC Brain Tumor Group (BTG) initiates and conducts academic clinical trials in patients with brain tumours, as well as designing and completing translational research associated with these trials. Its strategy is to challenge, re-define and develop standards of care in all controversial areas of diagnostic and therapeutic Neuro-Oncology, with a focus on diffuse gliomas of adulthood of WHO grades III to IV and, in recent years, also meningioma. The BTG has created several subcommittees that help design and conduct its scientific projects and cover key aspects of all projects such as imaging, translational research, quality of life, and quality assurance. The BTG is open for cooperative projects involving other EORTC groups as well external cooperation, for example with Neuro-Oncology networks in Canada, Australia and the US. The group aims to recruit and mentor junior European colleagues from all involved disciplines who are interested in pursuing an academic career in

Related News

[ALL NEWS >](#)

Interim Results of the CATNON Study – the Effects of Temozolomide

31 AUG

Tackling brain tumours – EORTC proves value of academic collaboration in the research of brain cancer

4 APR

EORTC helps improve standard of care for brain cancer patients

14 JUN

Related Events

[ALL EVENTS >](#)

8th Annual Brain Metastases Research and Emerging Therapy Conference

21 SEP - 22 SEP / MARSERLE, FR

Brain Tumour Group Meeting

10 OCT - 10 OCT / STOCKHOLM, SE

Recruiting Clinical Trials

[ALL CLINICAL TRIALS IN THIS RESEARCH FIELD >](#)

BTG committees

- Pathology and Translational Research (Pim French)
- Quality Assurance (Eva Ratzis)
- Quality of Life (Linda Dirven)
- Imaging (Marion Smits)
- Meningioma (Matthias Preusser)
- CNS metastasis (Emilie Le Rhun)

Mission statement

- The CNS Metastasis Committee orchestrates experimental and clinical research activities within the EORTC Brain Tumor Group.
- Scientific projects focus on the pathogenesis of brain and LM metastasis from solid tumors.
- Clinical projects encompass neuroimaging approaches and CSF studies, specifically with regards to response assessment.
- The committee seeks to develop clinical trial protocols exploring new agents.

Members of the group

Emilie Le Rhun, Lille (FR)

Martin Bendzus, Heidelberg (DE)

Dieta Bransdema (NL)

Frederic Dhermain, Paris (FR)

Matthias Preusser, Vienna (AT)

Riccardo Soffietti, Torino (IT)

Joerg-Christian Tonn, Munich (DE)

Pieter Wesseling, Amsterdam/Utrecht (NL)

Frank Winkler, Heidelberg (DE)

Validation of MRI RANO leptomeningeal metastases criteria

joined project with the BTG imaging group




- Coordinator: E Le Rhun (Zurich, Switzerland; Lille, France)
- Co-coordinator: M Bendszus (Heidelberg, Germany)
- Validation of the LANO grid by
 - 10 neuro-oncologists: D Brandsma, E Le Rhun, TJ Postma, P Roth, R Rudà, TJ Snidjers, M van den Bent, M Weller, F Winkler, P Wen
 - 9 neuroradiologists: M Bendzus, T Boulanger, J Capellades, J Furtner, J Hempel, A Castellano, M Smits, F Winklerhofer

EVER-LUNG


- Two parallel phase II multicenter randomized (1:1) studies will be proposed according to the EGFR/ALK mutation status determined per local assessment.
- patients **without** EGFR/ALK mutation will be randomized to **checkpoint inhibitor alone versus checkpoint inhibitor + SRS/SHFRT** (stereotactic hypofractionated radiotherapy) (**EVER-IO**)
- patients **with** EGFR/ALK mutation will be randomized to **EGFR TKI alone versus EGFR TKI + SRS/SHFRT** (**EVER-TKI**)

Randomized phase II trial of early radiosurgery **versus** delayed radiosurgery or other salvage treatment (EVER) with checkpoint inhibition (EVER-IO) for the treatment of patients with brain metastases from non-small cell lung cancer (NSCLC): EORTC-1807-BTG-LCG-ROG

- Study coordinator: E Le Rhun, Lille, France
- Writing committee:
 - BTG: Giuseppe Minniti, Michael Weller
 - LCG: Jesus Corral Jaime, Sanjay Popat, Matthias Guckenberger
 - ROG: Nicolaus Andratschke
- Primary objective: CNS-specific PFS rate at 6 months



New proposal in melanoma brain metastases



- Two parallel phase II multicenter randomized (1:1) in collaboration with ROG and the melanoma group: IO and Anti-BRAF

New proposals

- New projects are welcome!
- Requests for such projects should be submitted to the Chair of the EORTC BTG CNS Metastasis Committee.
- Funding: at the responsibility of the coordinator of the study, with the help of the EORTC and the CNS metastases committee.